Opioid dose risk, clinician and patient characteristics, and adherence to opioid prescribing recommendations in chronic non-cancer pain
DOI:
https://doi.org/10.5055/jom.0815Keywords:
clinician adherence, long-term opioid therapy, chronic noncancer painAbstract
Objective: This study aims to assess associations between morphine-equivalent daily dose (MEDD) of opioids, clinician and patient characteristics, and prescriber adherence to guidelines for long-term opioid therapy (LTOT) in chronic noncancer pain (CNCP) and to elucidate potential relationships associated with increased-risk opioid prescribing.
Design: Retrospective cross-sectional study.
Setting: Academic health system's 33 primary care clinics.
Patients: Adults (≥18 years old) prescribed LTOT (10 + outpatient prescriptions in the past year) for CNCP.
Main outcome measure(s): Electronic health record data on prescribed opioids (for MEDD), clinician/patient characteristics, and adherence rates to LTOT guideline-concordant recommendations.
Results: A total of 2,738 patients were eligible, 61.6 percent Lower, 15.7 percent Moderate, and 22.7 percent Higher Risk MEDD (<50, 50-89, and ≥90 mg/day, respectively). Higher MEDD correlated (p < 0.001) with Medicare insurance, current cigarette smoking, higher pain intensity and interference scores, and the presence of opioid use disorder diagnoses. Male clinicians more frequently prescribed (p < 0.001) and male patients were more likely to be prescribed (p < 0.001) higher MEDD compared to their female counterparts. Higher Risk MEDD was associated with higher coprescribed benzodiazepines (p = 0.015), lower depression screening (p = 0.048), urine drug testing (p = 0.003), comparable active treatment agreement (p = 0.189), opioid misuse risk screening (p = 0.619), and prescription drug monitoring checks (p = 0.203).
Conclusions: This study documented that higher MEDD was associated with risks of worse health outcomes without improved adherence to opioid prescribing guideline recommendations. Enhanced clinician awareness of factors associated with MEDD has the potential to mitigate LTOT risks and improve overall patient care.
References
Centers for Disease Control and Prevention: Prescribing practices: Changes in opioid prescribing practices. Available at https://www.cdc.gov/drugoverdose/data/prescribing/prescribing-practices.html. Accessed March 3, 2021.
Kiang MV, Humphreys K, Cullen MR, et al.: Opioid prescribing patterns among medical clinicians in the United States, 2003-17: Retrospective, observational study. BMJ. 2020; l6968. DOI: 10.1136/bmj.l6968. DOI: https://doi.org/10.1136/bmj.l6968
Bartoli A, Courtney K: What do the CDC guidelines mean for patients on long-term, high-dose opioids? Practical Pain Management. April 29, 2019. Available at https://www.practicalpainmanagement.com/resource-centers/opioid-monitoring-2nded/what-do-cdc-guidelines-mean-patients-long-term-high-dose. Accessed December 7, 2021.
Bialas P, Maier C, Klose P, et al.: Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: Systematic review and meta-analysis of open label extension trials with a study duration ≥26 weeks. Eur J Pain. 2020; 24(2): 265-278. DOI: 10.1002/ejp.1496. DOI: https://doi.org/10.1002/ejp.1496
Voon P, Karamouzian M, Kerr T: Chronic pain and opioid misuse: A review of reviews. Subst Abuse Treat Prev Policy. 2017; 12(1): 36. DOI: 10.1186/s13011-017-0120-7. DOI: https://doi.org/10.1186/s13011-017-0120-7
US Department of Health and Human Services Centers for Disease Control and Prevention: Assessing benefits and harms of opioid therapy. Available at https://www.cdc.gov/drugoverdose/pdf/assessing_benefits_harms_of_opioid_therapy-a.pdf. Accessed December 7, 2021.
Dowell D, Haegerich T, Chou R: CDC guidelines for prescribing opioids for chronic pain—United States. MMWR Recomm Rep. 2016; 65(1): 1-49. DOI: 10.15585/mmwr.rr6501e1. DOI: https://doi.org/10.15585/mmwr.rr6501e1
Busse JW, Craigie S, Juurlink DN, et al.: Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017; 189(18): E659-E666. DOI: 10.1503/cmaj.170363. DOI: https://doi.org/10.1503/cmaj.170363
Hossain MA, Asamoah-Boaheng M, Badejo OA, et al.: Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis. Health Psychol. 2020; 39(5): 430-451. DOI: 10.1037/hea0000830. DOI: https://doi.org/10.1037/hea0000830
Hubbard IJ, Harris D, Kilkenny MF, et al.: Adherence to clinical guidelines improves patient outcomes in Australian audit of stroke rehabilitation practice. Arch Phys Med Rehabil. 2012; 93(6): 965-971. DOI: 10.1016/j.apmr.2012.01.011. DOI: https://doi.org/10.1016/j.apmr.2012.01.011
Matthias MS, Parpart AL, Nyland KA, et al.: The patient–clinician relationship in chronic pain care: Clinicians' perspectives. Pain Med. 2010; 11(11): 1688-1697. DOI: 10.1111/j.1526-4637.2010.00980.x. DOI: https://doi.org/10.1111/j.1526-4637.2010.00980.x
Matthias MS, Talib TL, Huffman MA: Managing chronic pain in an opioid crisis: What is the role of shared decision-making? Health Commun. 2020; 35(10): 1239-1247. DOI: 10.1080/10410236.2019.1625000. DOI: https://doi.org/10.1080/10410236.2019.1625000
Zgierska A, Rabago D, Miller M: Impact of patient satisfaction ratings on physicians and clinical care. Patient Prefer Adherence. 2014; 8: 437-446. DOI: https://doi.org/10.2147/PPA.S59077
Zgierska A, Miller M, Rabago D: Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA. 2012; 307(13): 1377-1378. DOI: https://doi.org/10.1001/jama.2012.419
Coleman C, Lennon RP, Robinson JM, et al.: Sex disparities in opioid prescribing and patient outcomes. J Opioid Manag. 2022; 18(5): 435-445. DOI: 10.5055/jom.2022.0737. DOI: https://doi.org/10.5055/jom.2022.0737
Chen JH, Hom J, Richman I, et al.: Effect of opioid prescribing guidelines in primary care. Medicine (Baltimore). 2016; 95(35): e4760. DOI: https://doi.org/10.1097/MD.0000000000004760
Mattson CL, Tanz LJ, Quinn K, et al.: Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021; 70: 202-207. DOI: 10.15585/mmwr.mm7006a4. DOI: https://doi.org/10.15585/mmwr.mm7006a4
Zgierska AE, Vidaver RM, Smith P, et al.: Enhancing system-wide implementation of opioid prescribing guidelines in primary care: Protocol for a stepped-wedge quality improvement project. BMC Health Serv Res. 2018; 18(1): 415. DOI: 10.1186/s12913-018-3227-2. DOI: https://doi.org/10.1186/s12913-018-3227-2
Deyo RA, Smith DH, Johnson ES, et al.: Opioids for back pain patients: Primary care prescribing patterns and use of services. J Am Board Fam Med. 2011; 24(6): 717-727. DOI: https://doi.org/10.3122/jabfm.2011.06.100232
US Department of Health and Human Services, Guidance Portal: Opioid oral morphine milligram equivalent (MME) conversion factors table for prescription drug coverage. Issued by: Centers for Medicare & Medicaid Services (CMS). January 1, 2020. Available at https://www.hhs.gov/guidance/document/opioid-oral-morphine-milligram-equivalent-mme-conversionfactors-0. Accessed April 30, 2021.
US Department of Health and Human Services: Pain management best practices inter-agency task force report: Updates, gaps, inconsistencies, and recommendations. 2019. Retrieved from US Department of Health and Human Services website. Available at https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html. Accessed April 29, 2021.
Korff Jensen VM, Karoly MP: Assessing global pain severity by self-report in clinical and health services research. Spine. 2000; 25(24): 3140-3151. DOI: https://doi.org/10.1097/00007632-200012150-00009
US Department of Health and Human Services Data Resources: Analyzing opioid prescription data and oral morphine milligram equivalents (MME). Available at https://www.cdc.gov/drugoverdose/resources/data.html. Accessed April 29, 2021.
Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2–guidance. Pain Phys. 2012; 3S;15(3 Suppl): S67-S116. DOI: https://doi.org/10.36076/ppj.2012/15/S67
Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I–evidence assessment. Pain Phys. 2012; 3S;15(3 Suppl): S1-S66. DOI: https://doi.org/10.36076/ppj.2012/15/S1
Kroenke KS, Williams JB: The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9): 606-613. DOI: https://doi.org/10.1046/j.1525-1497.2001.016009606.x
Kroenke K, Spitzer R, Williams J: The patient health questionnaire-2: Validity of a two-item depression screener. Med Care. 2003; 41(11): 1284-1292. DOI: https://doi.org/10.1097/01.MLR.0000093487.78664.3C
Belgrade MJ, Schamber CD, Lindgren BR: The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. J Pain Sep. 2006; 7(9): 671-681. DOI: 10.1016/j.jpain.2006.03.001. DOI: https://doi.org/10.1016/j.jpain.2006.03.001
Scherrer JF, Salas J, Lustman PJ, et al.: Change in opioid dose and change in depression in a longitudinal primary care patient cohort. Pain. 2015; 156(2): 348-355. DOI: 10.1097/01.j.pain.0000460316.58110.a0. DOI: https://doi.org/10.1097/01.j.pain.0000460316.58110.a0
Cheatle MD, Falcone M, Dhingra L, et al.: Independent Association of Tobacco Use with opioid use disorder in patients of European ancestry with chronic non-cancer pain. Drug Alcohol Depend. 2020; 209: 107901. DOI: 10.1016/j.drugalcdep.2020.107901. DOI: https://doi.org/10.1016/j.drugalcdep.2020.107901
van Rijswijk SM, van Beek MHCT, Schoof GM, et al.: Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: A systematic review. Gen Hosp Psychiatry. 2019; 59: 37-50. DOI: 10.1016/j.genhosppsych.2019.04.008. DOI: https://doi.org/10.1016/j.genhosppsych.2019.04.008
Adams MH, Dobscha SK, Smith NX, et al.: Prevalence and correlates of low pain interference among patients with high pain intensity who are prescribed long-term opioid therapy. J Pain. 2018; 19(9): 1074-1081. DOI: 10.1016/j.jpain.2018.04.005. DOI: https://doi.org/10.1016/j.jpain.2018.04.005
Ólason M, Andrason RH, Jónsdóttir IH, et al.: Cognitive behavioral therapy for depression and anxiety in an interdisciplinary rehabilitation program for chronic pain: A randomized controlled trial with a 3-year follow-up. Int J Behav Med. 2018; 25: 55-66. DOI: 10.1007/s12529-017-9690-z. DOI: https://doi.org/10.1007/s12529-017-9690-z
US Food and Drug Administration: FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individual tapering. FDA Drug Safety Communication. 2019. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes. Accessed December 7, 2021.
Witkiewitz K, Vowles KE: Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: A critical review. Alcohol Clin Exp Res. 2018; 42(3): 478-488. DOI: DOI: https://doi.org/10.1111/acer.13594
1111/acer.13594.
Centers for Disease Control and Prevention: CDC advises against misapplication of the guidelines for prescribing opioids for chronic pain. CDC Newsroom. April 24, 2019. Available at https://www.cdc.gov/media/releases/2019/s0424-advisesmis-application-guideline-prescribing-opioids.html. Accessed December 7, 2021.
Zgierska AE, Robinson JM, Lennon RP, et al.: Increasing system-wide implementation of opioid prescribing guidelines in primary care: Findings from a non-randomized stepped-wedge quality improvement project. BMC Fam Pract. 2020; 21(1): 245. DOI: 10.1186/s12875-020-01320-9. DOI: https://doi.org/10.1186/s12875-020-01320-9
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
